{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T20:25:06Z","timestamp":1794428706381,"version":"4.9.1"},"reference-count":90,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.critrevonc.2025.104972","type":"journal-article","created":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T07:18:30Z","timestamp":1759216710000},"page":"104972","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["From innate power to intelligent design: The evolution of NK cell-based cancer immunotherapy"],"prefix":"10.1016","volume":"216","author":[{"given":"Israth Jahan","family":"Tuhin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong Jia","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masuma Akter","family":"Monty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin Wen","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.critrevonc.2025.104972_bib1","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002866","article-title":"NK cells enhance CAR-T cell antitumor efficacy by enhancing immune\/tumor cells cluster formation and improving CAR-T cell fitness","volume":"9","author":"Bachiller","year":"2021","journal-title":"J. Immunother. Cancer"},{"issue":"8","key":"10.1016\/j.critrevonc.2025.104972_bib2","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1158\/1078-0432.CCR-17-3196","article-title":"Complete remission with reduction of High-Risk clones following haploidentical NK-Cell therapy against MDS and AML","volume":"24","author":"Bj\u00f6rklund","year":"2018","journal-title":"Clin. Cancer Res"},{"issue":"14","key":"10.1016\/j.critrevonc.2025.104972_bib3","doi-asserted-by":"crossref","first-page":"4400","DOI":"10.1158\/1078-0432.CCR-18-3183","article-title":"Engineering the TGF\u03b2 receptor to enhance the therapeutic potential of natural killer cells as an immunotherapy for neuroblastoma","volume":"25","author":"Burga","year":"2019","journal-title":"Clin. Cancer Res"},{"key":"10.1016\/j.critrevonc.2025.104972_bib4","doi-asserted-by":"crossref","first-page":"2683","DOI":"10.3389\/fimmu.2019.02683","article-title":"CAR-Engineered NK cells for the treatment of glioblastoma: turning innate effectors into precision tools for cancer immunotherapy","volume":"10","author":"Burger","year":"2019","journal-title":"Front Immunol."},{"issue":"12","key":"10.1016\/j.critrevonc.2025.104972_bib5","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1360\/TB-2019-0787","article-title":"Application of nanomaterials in antitumor immune response enhancement","volume":"65","author":"Chen","year":"2020","journal-title":"Chin. Sci. Bull."},{"issue":"19","key":"10.1016\/j.critrevonc.2025.104972_bib6","doi-asserted-by":"crossref","first-page":"27764","DOI":"10.18632\/oncotarget.8526","article-title":"A combinational therapy of EGFR-CAR NK cells and oncolytic herpes simplex virus 1 for breast cancer brain metastases","volume":"7","author":"Chen","year":"2016","journal-title":"Oncotarget"},{"issue":"568","key":"10.1016\/j.critrevonc.2025.104972_bib7","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaz5618","article-title":"iPSC-derived NK cells maintain high cytotoxicity and enhance in vivo tumor control in concert with t cells and anti-PD-1 therapy","volume":"12","author":"Cichocki","year":"2020","journal-title":"Sci. Transl. Med"},{"key":"10.1016\/j.critrevonc.2025.104972_bib8","unstructured":"Clin, L., FT596 as a Monotherapy and in Combination With Anti-CD20 Monoclonal Antibodies. \u3008https:\/\/clin.larvol.com\/trial-detail\/NCT04245722\u3009."},{"key":"10.1016\/j.critrevonc.2025.104972_bib9","unstructured":"ClinicalTrials.gov, 2019-09-26. A Study of MG4101 (Allogeneic Natural Killer Cell) for Intermediate-stage of Hepatocellular Carcinoma. \u3008https:\/\/clinicaltrials.gov\/search?term=NCT02854839\u3009."},{"key":"10.1016\/j.critrevonc.2025.104972_bib10","unstructured":"ClinicalTrials.gov 2022-02-02. Study of Anti-5T4 CAR-NK Cell Therapy in Advanced Solid Tumors. \u3008https:\/\/clinicaltrials.gov\/study\/NCT05194709?term=NCT05194709&rank=1\u3009."},{"key":"10.1016\/j.critrevonc.2025.104972_bib11","unstructured":"ClinicalTrials.gov, 2024-08-19. QUILT-3.064: PD-L1 t-haNK In Subjects With Locally Advanced Or Metastatic Solid Cancers. \u3008https:\/\/clinicaltrials.gov\/study\/NCT04050709?term=NCT04050709&rank=1\u3009."},{"key":"10.1016\/j.critrevonc.2025.104972_bib12","unstructured":"ClinicalTrials.gov, 2024-10-24. FT538 in Combination With Daratumumab in AML Acute Myeloid Leukemia. \u3008https:\/\/clinicaltrials.gov\/study\/NCT04714372?tab=results\u3009."},{"key":"10.1016\/j.critrevonc.2025.104972_bib13","unstructured":"ClinicalTrials.gov, 2025-08-01. Immunotherapy Combination: Irradiated PD-L1 CAR-NK Cells Plus Pembrolizumab Plus N-803 for Subjects With Recurrent\/Metastatic Gastric or Head and Neck Cancer. \u3008https:\/\/www.clinicaltrials.gov\/study\/NCT04847466\u3009."},{"key":"10.1016\/j.critrevonc.2025.104972_bib14","unstructured":"ClinicalTrials.gov, 2025-08-13. Phase I\/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse\/Refractory Hematological Malignances. \u3008https:\/\/clinicaltrials.gov\/study\/NCT05092451\u3009."},{"key":"10.1016\/j.critrevonc.2025.104972_bib15","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.913215","article-title":"From CD16a biology to antibody-dependent cell-mediated cytotoxicity improvement","volume":"13","author":"Co\u00ebnon","year":"2022","journal-title":"Front. Immunol."},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104972_bib16","doi-asserted-by":"crossref","DOI":"10.1002\/cti2.1274","article-title":"CAR-NK cells: the next wave of cellular therapy for cancer","volume":"10","author":"Daher","year":"2021","journal-title":"Clin. Transl. Immunol."},{"issue":"7","key":"10.1016\/j.critrevonc.2025.104972_bib17","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1038\/ni.3470","article-title":"CIS is a potent checkpoint in NK cell-mediated tumor immunity","volume":"17","author":"Delconte","year":"2016","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.critrevonc.2025.104972_bib18","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.canlet.2020.09.021","article-title":"NK cells-directed therapies target circulating tumor cells and metastasis","volume":"497","author":"Dianat-Moghadam","year":"2021","journal-title":"Cancer Lett."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104972_bib19","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1002\/jcp.26878","article-title":"Natural killer cell-based immunotherapy: from transplantation toward targeting cancer stem cells","volume":"234","author":"Dianat-Moghadam","year":"2018","journal-title":"J. Cell Physiol."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104972_bib20","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2019-000450","article-title":"PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations","volume":"8","author":"Fabian","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.critrevonc.2025.104972_bib21","article-title":"Fate therapeutics highlights iPSC-derived, Off-the-shelf CAR NK cell programs for multiple myeloma at","volume":"2022","author":"Fate Therapeutics","year":"2022","journal-title":"ASH Annu. Meet."},{"issue":"13_ement","key":"10.1016\/j.critrevonc.2025.104972_bib22","article-title":"Abstract SY30-02: NK cells remember: engineering NK cell memory-like responses for cancer immunotherapy","volume":"81","author":"Fehniger","year":"2021","journal-title":"Cancer Res."},{"issue":"16","key":"10.1016\/j.critrevonc.2025.104972_bib23","doi-asserted-by":"crossref","DOI":"10.1002\/adhm.202100598","article-title":"Selenium nanoparticles for biomedical applications: from development and characterization to therapeutics","volume":"10","author":"Ferro","year":"2021","journal-title":"Adv. Health Mater."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104972_bib24","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001428","article-title":"Interleukin-15 and cancer: some solved and many unsolved questions","volume":"8","author":"Fiore","year":"2020","journal-title":"J. Immunother. Cancer"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104972_bib25","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1038\/s41392-024-01824-1","article-title":"Combination therapy with oncolytic virus and t cells or mRNA vaccine amplifies antitumor effects","volume":"9","author":"Fu","year":"2024","journal-title":"Signal Transduct. Target Ther."},{"issue":"12","key":"10.1016\/j.critrevonc.2025.104972_bib26","doi-asserted-by":"crossref","DOI":"10.1002\/adma.201907568","article-title":"Selenium-Containing nanoparticles combine the NK cells mediated immunotherapy with radiotherapy and chemotherapy","volume":"32","author":"Gao","year":"2020","journal-title":"Adv. Mater."},{"key":"10.1016\/j.critrevonc.2025.104972_bib27","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1182\/blood-2021-148618","article-title":"iPSC-derived natural killer cells and macrophages synergistically kill acute myeloid leukemia blasts","volume":"138","author":"Goldenson","year":"2021","journal-title":"Blood"},{"issue":"6_ement","key":"10.1016\/j.critrevonc.2025.104972_bib28","article-title":"Generating functional CAR-NK cells for cancer immunotherapy","volume":"84","author":"Gregoli","year":"2024","journal-title":"Cancer Res."},{"issue":"7_ement","key":"10.1016\/j.critrevonc.2025.104972_bib29","article-title":"ADAM17 knockout NK or CAR NK cells augment antibody dependent cellular cytotoxicity (ADCC) and anti-tumor activity","volume":"83","author":"Guo","year":"2023","journal-title":"Cancer Res."},{"key":"10.1016\/j.critrevonc.2025.104972_bib30","series-title":"380 preliminary results of an ongoing phase I trial of FT500, a first-in-class, off-the-shelf, induced pluripotent stem cell (iPSC) derived natural killer (NK) cell therapy in advanced solid tumors","author":"Hong","year":"2020"},{"key":"10.1016\/j.critrevonc.2025.104972_bib31","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1182\/blood-2020-137715","volume":"136","author":"Janakiram","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2025.104972_bib32","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1303605","article-title":"NK cell exhaustion in the tumor microenvironment","volume":"14","author":"Jia","year":"2023","journal-title":"Front Immunol."},{"issue":"52","key":"10.1016\/j.critrevonc.2025.104972_bib33","doi-asserted-by":"crossref","first-page":"86359","DOI":"10.18632\/oncotarget.13411","article-title":"An NK cell line (haNK) expressing high levels of granzyme and engineered to express the high affinity CD16 allele","volume":"7","author":"Jochems","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.critrevonc.2025.104972_bib34","series-title":"116 development of logic gated CAR-NK cells for the treatment of solid tumors","author":"Junca","year":"2021"},{"issue":"15","key":"10.1016\/j.critrevonc.2025.104972_bib35","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22158035","article-title":"Combining cancer vaccines with immunotherapy: establishing a new immunological approach","volume":"22","author":"Kim","year":"2021","journal-title":"Int J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104972_bib36","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1186\/s12885-019-6387-5","article-title":"Biological treatment of pediatric sarcomas by combined virotherapy and NK cell therapy","volume":"19","author":"Klose","year":"2019","journal-title":"BMC Cancer"},{"issue":"11","key":"10.1016\/j.critrevonc.2025.104972_bib37","doi-asserted-by":"crossref","first-page":"2650","DOI":"10.1016\/j.immuni.2021.09.002","article-title":"Early IFN-\u03b1 signatures and persistent dysfunction are distinguishing features of NK cells in severe COVID-19","volume":"54","author":"Kr\u00e4mer","year":"2021","journal-title":"Immunity"},{"key":"10.1016\/j.critrevonc.2025.104972_bib38","doi-asserted-by":"crossref","DOI":"10.2174\/0115733947383194250701073137","article-title":"Advancing NK cell therapies: expansion and activation for Next-Generation immunotherapy","author":"Kumar","year":"2025","journal-title":"Curr. Cancer Ther. Rev."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104972_bib39","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1186\/s13045-022-01382-5","article-title":"Natural killer cells in clinical development as non-engineered, engineered, and combination therapies","volume":"15","author":"Lamers-Kok","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104972_bib40","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.omto.2020.02.001","article-title":"NK cells augment oncolytic adenovirus cytotoxicity in ovarian cancer","volume":"16","author":"Leung","year":"2020","journal-title":"Mol. Ther. Oncolytics"},{"issue":"8","key":"10.1016\/j.critrevonc.2025.104972_bib41","doi-asserted-by":"crossref","DOI":"10.3390\/v13081450","article-title":"Strategies to optimise oncolytic viral therapies: the role of natural killer cells","volume":"13","author":"Leung","year":"2021","journal-title":"Viruses"},{"key":"10.1016\/j.critrevonc.2025.104972_bib42","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.3389\/fimmu.2019.01262","article-title":"Enhanced bone marrow homing of natural killer cells following mRNA transfection with Gain-of-Function variant CXCR4(R334X)","volume":"10","author":"Levy","year":"2019","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104972_bib43","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2019-000131","article-title":"CCL5-armed oncolytic virus augments CCR5-engineered NK cell infiltration and antitumor efficiency","volume":"8","author":"Li","year":"2020","journal-title":"J. Immunother. Cancer"},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104972_bib44","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.tips.2024.12.004","article-title":"Boosting CAR-T cell therapy through vaccine synergy","volume":"46","author":"Li","year":"2025","journal-title":"Trends Pharm. Sci."},{"issue":"9","key":"10.1016\/j.critrevonc.2025.104972_bib45","doi-asserted-by":"crossref","first-page":"11067","DOI":"10.1021\/acsnano.9b10103","article-title":"Boosting natural killer Cell-Based cancer immunotherapy with Selenocystine\/Transforming growth Factor-Beta Inhibitor-Encapsulated nanoemulsion","volume":"14","author":"Liu","year":"2020","journal-title":"ACS Nano"},{"issue":"6","key":"10.1016\/j.critrevonc.2025.104972_bib46","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1056\/NEJMoa1910607","article-title":"Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors","volume":"382","author":"Liu","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.critrevonc.2025.104972_bib47","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1056\/NEJMoa1910607","article-title":"Use of CAR-Transduced natural killer cells in CD19-Positive lymphoid tumors","volume":"382","author":"Liu","year":"2020","journal-title":"N. Engl. J. Med"},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104972_bib48","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1038\/leu.2017.226","article-title":"Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent antitumor activity","volume":"32","author":"Liu","year":"2018","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.critrevonc.2025.104972_bib49","first-page":"3395","article-title":"TGF-\u03b21 secreted by M2 phenotype macrophages enhances the stemness and migration of glioma cells via the SMAD2\/3 signalling pathway","volume":"42","author":"Liu","year":"2018","journal-title":"Int. J. Mol. Med"},{"key":"10.1016\/j.critrevonc.2025.104972_bib50","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.molimm.2020.04.016","article-title":"A novel chimeric PD1-NKG2D-41BB receptor enhances antitumor activity of NK92 cells against human lung cancer H1299 cells by triggering pyroptosis","volume":"122","author":"Lu","year":"2020","journal-title":"Mol. Immunol."},{"issue":"6","key":"10.1016\/j.critrevonc.2025.104972_bib51","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11060769","article-title":"Natural killer cells as allogeneic effectors in adoptive cancer immunotherapy","volume":"11","author":"Lupo","year":"2019","journal-title":"Cancers"},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104972_bib52","doi-asserted-by":"crossref","first-page":"ii194","DOI":"10.1093\/neuonc\/noaa215.812","article-title":"RTID-07. Human placental hematopoietic stem cell derived natural killer cells (CYNK-001) for treatment of recurrent glioblastoma","volume":"22","author":"Majd","year":"2020","journal-title":"Neuro Oncol."},{"issue":"22","key":"10.1016\/j.critrevonc.2025.104972_bib53","doi-asserted-by":"crossref","first-page":"5552","DOI":"10.1158\/1078-0432.CCR-18-0945","article-title":"Phase I trial of ALT-803, a novel recombinant IL15 complex, in patients with advanced solid tumors","volume":"24","author":"Margolin","year":"2018","journal-title":"Clin. Cancer Res"},{"issue":"9","key":"10.1016\/j.critrevonc.2025.104972_bib54","doi-asserted-by":"crossref","DOI":"10.1096\/fj.202100025R","article-title":"\"Built-in\" PD-1 blocker to rescue NK-92 activity from PD-L1-mediated tumor escape mechanisms","volume":"35","author":"Mensali","year":"2021","journal-title":"FASEB J."},{"key":"10.1016\/j.critrevonc.2025.104972_bib55","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2023.101073","article-title":"Advances in NK cell therapy for hematologic malignancies: NK source, persistence and tumor targeting","volume":"60","author":"Merino","year":"2023","journal-title":"Blood Rev."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104972_bib56","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s12943-021-01335-5","article-title":"mRNA vaccine for cancer immunotherapy","volume":"20","author":"Miao","year":"2021","journal-title":"Mol. Cancer"},{"issue":"5","key":"10.1016\/j.critrevonc.2025.104972_bib57","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1097\/CJI.0000000000000082","article-title":"Engineering NK cells modified with an EGFRvIII-specific chimeric antigen receptor to overexpress CXCR4 improves immunotherapy of CXCL12\/SDF-1\u03b1-secreting glioblastoma","volume":"38","author":"M\u00fcller","year":"2015","journal-title":"J. Immunother."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104972_bib58","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/s41571-020-0426-7","article-title":"Exploring the NK cell platform for cancer immunotherapy","volume":"18","author":"Myers","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104972_bib59","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.omto.2019.12.006","article-title":"CXCR1 expression to improve Anti-Cancer efficacy of intravenously injected CAR-NK cells in mice with peritoneal xenografts","volume":"16","author":"Ng","year":"2020","journal-title":"Mol. Ther. Oncolytics"},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104972_bib60","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.7150\/thno.65516","article-title":"Engineered extracellular vesicle-based sonotheranostics for dual stimuli-sensitive drug release and photoacoustic imaging-guided chemo-sonodynamic cancer therapy","volume":"12","author":"Nguyen Cao","year":"2022","journal-title":"Theranostics"},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104972_bib61","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1158\/2326-6066.CIR-18-0572","article-title":"NK cells expressing a chimeric activating receptor eliminate MDSCs and rescue impaired CAR-T cell activity against solid tumors","volume":"7","author":"Parihar","year":"2019","journal-title":"Cancer Immunol. Res"},{"issue":"16","key":"10.1016\/j.critrevonc.2025.104972_bib62","doi-asserted-by":"crossref","first-page":"13819","DOI":"10.1021\/acsami.7b02258","article-title":"Immunomodulatory magnetic microspheres for augmenting tumor-specific infiltration of natural killer (NK) cells","volume":"9","author":"Park","year":"2017","journal-title":"ACS Appl. Mater. Interfaces"},{"issue":"5","key":"10.1016\/j.critrevonc.2025.104972_bib63","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1080\/19420862.2018.1466767","article-title":"The \"less-is-more\" in therapeutic antibodies: afucosylated anti-cancer antibodies with enhanced antibody-dependent cellular cytotoxicity","volume":"10","author":"Pereira","year":"2018","journal-title":"MAbs"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104972_bib64","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.ymthe.2019.10.009","article-title":"A genetically engineered primary human natural killer cell platform for cancer immunotherapy","volume":"28","author":"Pomeroy","year":"2020","journal-title":"Mol. Ther."},{"issue":"9","key":"10.1016\/j.critrevonc.2025.104972_bib65","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1084\/jem.20181454","article-title":"NK cells switch from granzyme b to death receptor-mediated cytotoxicity during serial killing","volume":"216","author":"Prager","year":"2019","journal-title":"J. Exp. Med"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104972_bib66","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1186\/s12935-023-03134-y","article-title":"The nexus of natural killer cells and melanoma tumor microenvironment: crosstalk, chemotherapeutic potential, and innovative NK cell-based therapeutic strategies","volume":"23","author":"Rahimi","year":"2023","journal-title":"Cancer Cell Int"},{"issue":"23","key":"10.1016\/j.critrevonc.2025.104972_bib67","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.1182\/blood-2017-12-823757","article-title":"First-in-human phase 1 clinical study of the IL-15 superagonist complex ALT-803 to treat relapse after transplantation","volume":"131","author":"Romee","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2025.104972_bib68","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.822298","article-title":"Taking lessons from CAR-T cells and going beyond: tailoring design and signaling for CAR-NK cells in cancer therapy","volume":"13","author":"Ruppel","year":"2022","journal-title":"Front Immunol."},{"issue":"14","key":"10.1016\/j.critrevonc.2025.104972_bib69","doi-asserted-by":"crossref","first-page":"3856","DOI":"10.7150\/thno.25149","article-title":"Expansion of allogeneic NK cells with efficient antibody-dependent cell cytotoxicity against multiple tumors","volume":"8","author":"Sanchez-Martinez","year":"2018","journal-title":"Theranostics"},{"key":"10.1016\/j.critrevonc.2025.104972_bib70","author":"Seymour","year":"2023","journal-title":"NKX101 Demonstr. Early Act. Relapsed\/Refract. AML"},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104972_bib71","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1038\/s41573-019-0052-1","article-title":"NK cells for cancer immunotherapy","volume":"19","author":"Shimasaki","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104972_bib72","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1186\/s12943-024-02045-4","article-title":"Natural killer cell-derived exosome-based cancer therapy: from biological roles to clinical significance and implications","volume":"23","author":"Si","year":"2024","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.critrevonc.2025.104972_bib73","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.847008","article-title":"Genetic engineering and enrichment of human NK cells for CAR-Enhanced immunotherapy of hematological malignancies","volume":"13","author":"Soldierer","year":"2022","journal-title":"Front Immunol."},{"issue":"8","key":"10.1016\/j.critrevonc.2025.104972_bib74","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13081988","article-title":"Harnessing natural killer cells in cancer immunotherapy: a review of mechanisms and novel therapies","volume":"13","author":"St-Pierre","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.critrevonc.2025.104972_bib75","doi-asserted-by":"crossref","first-page":"589","DOI":"10.2147\/ITT.S512700","article-title":"TGF-\u03b2 decreases NK cell mobility and cytotoxic efficacy in complex in vitro models of the leukemia microenvironment","volume":"14","author":"\u0160vubov\u00e1","year":"2025","journal-title":"Immunotargets Ther."},{"key":"10.1016\/j.critrevonc.2025.104972_bib76","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.jconrel.2023.10.007","article-title":"Engineering CAR-NK cell derived exosome disguised nano-bombs for enhanced HER2 positive breast cancer brain metastasis therapy","volume":"363","author":"Tao","year":"2023","journal-title":"J. Control Release"},{"issue":"7","key":"10.1016\/j.critrevonc.2025.104972_bib77","doi-asserted-by":"crossref","DOI":"10.1002\/mco2.626","article-title":"Natural killer cells in cancer immunotherapy","volume":"5","author":"Wang","year":"2024","journal-title":"MedComm"},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104972_bib78","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1016\/j.gendis.2022.07.009","article-title":"Functional crosstalk and regulation of natural killer cells in tumor microenvironment: significance and potential therapeutic strategies","volume":"10","author":"Wang","year":"2023","journal-title":"Genes Dis."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104972_bib79","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/s41420-024-01815-9","article-title":"Breakthrough of solid tumor treatment: CAR-NK immunotherapy","volume":"10","author":"Wang","year":"2024","journal-title":"Cell Death Discov."},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104972_bib80","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1007\/s00262-017-1959-1","article-title":"Augmented anti-tumor activity of NK-92 cells expressing chimeric receptors of TGF-\u03b2R II and NKG2D","volume":"66","author":"Wang","year":"2017","journal-title":"Cancer Immunol. Immunother."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104972_bib81","article-title":"Extracellular vesicles derived from natural killer cells use multiple cytotoxic proteins and killing mechanisms to target cancer cells","volume":"8","author":"Wu","year":"2019","journal-title":"J. Extra Vesicles"},{"key":"10.1016\/j.critrevonc.2025.104972_bib82","article-title":"Natural killer Cell-Derived extracellular vesicles: novel players in cancer immunotherapy","volume":"12","author":"Wu","year":"2021","journal-title":"Front Immunol."},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104972_bib83","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.jcyt.2016.12.005","article-title":"Cord blood natural killer cells expressing a dominant negative TGF-\u03b2 receptor: implications for adoptive immunotherapy for glioblastoma","volume":"19","author":"Yvon","year":"2017","journal-title":"Cytotherapy"},{"key":"10.1016\/j.critrevonc.2025.104972_bib84","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.jconrel.2024.02.033","article-title":"Adoptive cell therapy for solid tumors beyond CAR-T: current challenges and emerging therapeutic advances","volume":"368","author":"Zhang","year":"2024","journal-title":"J. Control Release"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104972_bib85","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1186\/s12885-023-11806-1","article-title":"Co-expression of IL-21-Enhanced NKG2D CAR-NK cell therapy for lung cancer","volume":"24","author":"Zhang","year":"2024","journal-title":"BMC Cancer"},{"issue":"12","key":"10.1016\/j.critrevonc.2025.104972_bib86","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1038\/s41590-019-0511-1","article-title":"Mitochondrial fragmentation limits NK cell-based tumor immunosurveillance","volume":"20","author":"Zheng","year":"2019","journal-title":"Nat. Immunol."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104972_bib87","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.stem.2020.05.008","article-title":"Metabolic reprograming via deletion of CISH in human iPSC-Derived NK cells promotes in vivo persistence and enhances Anti-tumor activity","volume":"27","author":"Zhu","year":"2020","journal-title":"Cell Stem Cell"},{"issue":"6","key":"10.1016\/j.critrevonc.2025.104972_bib88","first-page":"399","article-title":"Pluripotent stem cell\u2013derived NK cells with high-affinity noncleavable CD16a mediate improved antitumor activity. Blood","volume":"135","author":"Zhu","year":"2020","journal-title":"J. Am. Soc. Hematol."},{"issue":"6","key":"10.1016\/j.critrevonc.2025.104972_bib89","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1182\/blood.2019000621","article-title":"Pluripotent stem cell-derived NK cells with high-affinity noncleavable CD16a mediate improved antitumor activity","volume":"135","author":"Zhu","year":"2020","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104972_bib90","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1166\/jbn.2019.2697","article-title":"Magnetic resonance imaging of the human ferritin heavy chain reporter gene carried by dendrimer-entrapped gold nanoparticles","volume":"15","author":"Zhuo","year":"2019","journal-title":"J. Biomed. Nanotechnol."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842825003609?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842825003609?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T14:44:22Z","timestamp":1773153862000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842825003609"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":90,"alternative-id":["S1040842825003609"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2025.104972","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"From innate power to intelligent design: The evolution of NK cell-based cancer immunotherapy","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2025.104972","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104972"}}